| How I Treat Paroxysmal nocturnal hemoglobinuria |
|
Blood |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Daratumumab in transfusion-dependent patients with low or intermediate-1 risk myelodysplastic syndromes |
|
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
| Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes |
|
Journal of clinical oncology: official journal of the American Society Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
| Treatment options for lower-risk myelodysplastic syndromes. Where are we now? |
|
Therapeutic Advances in Hematology |
Myelodysplastic Syndromes (MDS) |
| Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management" |
|
American Journal of Hematology |
Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN) |
| Effectiveness and safety of tacrolimus with or without eltrombopag, as a part of immunosuppressive treatment of aplastic anemia in adults: a retrospective case series |
|
Annals of Hematology |
Aplastic Anemia |
| Risk factors for de novo and therapy-related myelodysplastic syndromes (MDS) |
|
Cancer Causes & Control : CCC |
Myelodysplastic Syndromes (MDS) |
| The evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia |
|
Seminars in Hematology |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Allogeneic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes and Prevention of Relapse |
|
Clinical Lymphoma , Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
| Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study |
|
Journal of clinical oncology: official journal of the American Society Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
